Spiriva and Tafinlar drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Spiriva and Tafinlar. Common interactions include death among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people who take Spiriva and Tafinlar have. It is created by eHealthMe based on reports of 21 people who take Spiriva and Tafinlar from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 01, 2022

21 people who take Spiriva and Tafinlar together, and have interactions are studied.


What is Spiriva?

Spiriva has active ingredients of tiotropium bromide monohydrate. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 146,199 Spiriva users for its effectiveness, alternative drugs and more.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 13,211 Tafinlar users for its effectiveness, alternative drugs and more.

Number of Spiriva and Tafinlar reports submitted per year:

Spiriva and Tafinlar drug interactions.

Common Spiriva and Tafinlar drug interactions by gender *:

female:

  1. Death
  2. Diarrhoea
  3. Adverse drug reaction
  4. Blood pressure decreased
  5. Decreased appetite
  6. Decubitus ulcer
  7. Fatigue
  8. Nausea
  9. Septic shock

male:

  1. Pyrexia
  2. Death
  3. Non-small cell lung cancer
  4. Oral candidiasis
  5. Pneumonia
  6. Staphylococcal infection
  7. Bronchitis
  8. Cough
  9. Generalised oedema
  10. Ascites

Common Spiriva and Tafinlar drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Decubitus ulcer
  2. Septic shock

60+:

  1. Malignant neoplasm progression
  2. Sleep disorder
  3. Cough
  4. Death
  5. Decreased appetite
  6. Generalised oedema
  7. Ascites
  8. Metastatic malignant melanoma
  9. Adverse drug reaction
  10. Anaemia

Common conditions people have *:

  1. Malignant Melanoma (skin cancer rises from melancytes): 7 people, 33.33%
  2. Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 6 people, 28.57%
  3. High Blood Pressure: 4 people, 19.05%
  4. Sleep Disorder: 3 people, 14.29%
  5. Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 14.29%
  6. Pleural Effusion (water on the lungs): 3 people, 14.29%
  7. Lung Cancer - Non-Small Cell (lung cancer): 3 people, 14.29%
  8. High Blood Cholesterol: 3 people, 14.29%
  9. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 14.29%
  10. Gastric Ulcer (stomach ulcer): 3 people, 14.29%

* Approximation only. Some reports may have incomplete information.

Do you take Spiriva and Tafinlar?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Spiriva and Tafinlar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Spiriva interactions:

Browse all interactions between Spiriva and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Tafinlar interactions:

Browse all interactions between Tafinlar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tiotropium bromide monohydrate and dabrafenib mesylate (the active ingredients of Spiriva and Tafinlar, respectively), and Spiriva and Tafinlar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Spiriva and Tafinlar.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: